ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Portfolio Tracker
Get an update on your stocks every day. See earnings revisions, new reports and Zacks Rank changes at a glance. Click here to learn more.

Quote:

Search for Ticker

Free Membership

Search:

MYL: Mylan Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

MYLAN INC (NASD)
MYL	17.55	0.12	(0.69%)	Vol. 4,093,232	16:00 ET

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.

General Information

MYLAN INC

1500 Corporate Drive Canonsburg, PA 15317 Phone: 724 514-1800 Fax: - Web: www.mylan.com Email: investor_relations@mylan.com

Industry	MED-GENERIC DRG
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	02/18/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	17.43
52 Week High	18.10
52 Week Low	7.69
Beta	0.53
20 Day Moving Average	6,801,127.00
Target Price Consensus	19

% Price Change
4 Week	8.80
12 Week	18.58
YTD	77.45

% Price Change Relative to S&P 500
4 Week	7.63
12 Week	11.80
YTD	46.86

Share Information
Shares Outstanding (millions)	305.33
Market Capitalization (millions)	5,358.56
Short Ratio	9.45
Last Split Date	10/09/2003

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	-0.13
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	0.29
Current Year EPS Consensus Estimate	1.26
Estimated Long-Term EPS Growth Rate	17.70
Next EPS Report Date	02/18/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	1.90
30 Days Ago	1.90
60 Days Ago	1.90
90 Days Ago	1.82

Fundamental Ratios

P/E
Current FY Estimate:	13.90
Trailing 12 Months:	15.67
PEG Ratio	0.78

EPS Growth
vs. Previous Year	39.13%
vs. Previous Quarter	0.00%

Sales Growth
vs. Previous Year	-23.71%
vs. Previous Quarter:	-0.23%

Price Ratios
Price/Book	1.75
Price/Cash Flow	6.61
Price / Sales	1.08

ROE
09/30/09	20.48
06/30/09	20.56
03/31/09	16.75

ROA
09/30/09	5.62
06/30/09	5.56
03/31/09	4.48

Current Ratio
09/30/09	2.06
06/30/09	2.13
03/31/09	2.17

Quick Ratio
09/30/09	1.35
06/30/09	1.37
03/31/09	1.41

Operating Margin
09/30/09	11.73
06/30/09	10.82
03/31/09	9.10

Net Margin
09/30/09	3.76
06/30/09	12.75
03/31/09	10.51

Pre-Tax Margin
09/30/09	3.76
06/30/09	12.75
03/31/09	10.51

Book Value
09/30/09	10.06
06/30/09	9.54
03/31/09	8.69

Inventory Turnover
09/30/09	2.79
06/30/09	2.78
03/31/09	2.78

Debt-to-Equity
09/30/09	1.67
06/30/09	1.71
03/31/09	1.87

Debt to Capital
09/30/09	62.54
06/30/09	63.09
03/31/09	65.21


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research